patients of open heart surgery with hypertention
Conditions
Interventions
irvesartan (+)
irvesartan (-)
Sponsors
Department of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Informed consent was obtained from patients
Exclusion criteria
Exclusion criteria: 1) a history of hypersensitivity to any component of irbesartan 2) pregnant or potentially pregnant women 3) severe hypertension 4) persistent atrial fibrillation 5) treated with antiarrhythmic drug 6) atrioventricular block 7) parenteral antihypertensive drugs indicated in hypertensive emergency 8) undergoing hemodialysis 9) myocardial infarction within 6 months before study entry, or stroke attack 10) severe heart failure, or arrhythmia 11) severe renal dysfunction 12) severe liver dysfunction 13) uncontrolled diabetes 14) participated in other clinical trials, or treated with the drug test within 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Existence of atrial fibrillation and side effects | — |
Secondary
| Measure | Time frame |
|---|---|
| length of intensive care unit, length of postoperative stay, incidence of atrial fibrillation | — |
Countries
Japan
Contacts
Public ContactRyo Suzuki
Department of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine Division of Cardiac Surgery
Outcome results
None listed